Here at @RadOncUH we train our residents to become the trailblazers for tomorrow’s standard of care.
@lauren_henke@angela_jia_
Full video here: https://t.co/0cbh6iHggA
🏆 Gold Award Winner! Our RadOnc Residency video was recognized as Best Video Content (Over 2min) at the 2026 eHealthcare Awards. 🙏🏼🙏🏼to everyone who helped bring our story to life.
https://t.co/8fftbPgeX0
@lauren_henke@angela_jia_@DrSpratticus@HaleyPerlow@PranshuMohindra
Here at @RadOncUH we train our residents to become the trailblazers for tomorrow’s standard of care.
@lauren_henke@angela_jia_
Full video here: https://t.co/0cbh6iHggA
Proud to be on Luke’s cheer squad today as he rang the bell for @Browns#CrucialCatch for cancer screening. Luke’s a ⭐️, bravely sharing his story of young-onset colorectal cancer. Get screened, & if you have symptoms, get tested ASAP. It might save your life. 💙 GO BROWNS! 🧡
Amazing trip to Prague for @ESTRO_RT ’s workshop on direct-to-unit (née sim-free) RT. Got to watch @APrice_BeamOn lecture as faculty & represent our creative @RadOncUH team & collaborators, see many dear friends, & join in as ad-hoc guest physician faculty on a topic I love!
Make that THREE papers this week! 🚨
RAPTOR is out: 3,120 men & 11 RCTs. After RT alone, being BCR-free at 5y marked a functional-cure benchmark (8y DM 6.6%; 10y PCSM 2.5%). W/ ADT, late metastatic risk persisted.
https://t.co/LfyPWnfJ5c @AmarUKishan@DrSpratticus@alison_tree
Two papers in a week! 🚨
Now out in @IJROBP: after testosterone recovery following RT+ADT, faster PSA kinetics were associated w/ progression but the relationship with metastatic risk was inconsistent. https://t.co/0fqNz80QKH
Just days after our NADIR validation in ARCHES! 🔬
Another @RadOncUH PGY-4 with an 🎤🔥oral presentation today! @SamLM_MD killing it presenting the ✅feasibility of planning on HyperSight CBCT on TrueBeam in a prospective trial- @SiemensHealth Varian CMO @DrDee2014 & physics PI @APrice_BeamOn both front row, cheering him on!
NCT05975619
@RadOncUH PGY-4 @QingLi_MDPhD 🔥crushing it with an(other) 🎤oral presentation this morning on her #HolmanPathway work on how RT modulates HER2 expression and trastuzuman deruxtecan response in HER2 low metastatic breast cancer.
#bcsm@TyMillerLab
@ASTRO_org#ASTRO26 trial data ➡️how we approach 🧠mets from SCLC has officially, fundamentally changed.
🤔Want to know how to put @SWOG MAVERICK & @NRGonc CC009 together?
🎧Listen to our @NRGonc podcast about BOTH trials with Chad Rusthoven!
👉🏼 https://t.co/ASiC54zCds
#btsm
Loving being @S_W_R_O’s event with some of the very incredible women in rad onc that I look up to very much, and am inspired by on the daily. Amazing way to close out the day at @ASTRO_org#ASTRO26. Super thrilled to have @luliacevedo joining @RadOncUH faculty for H&N, too 🎉❤️
Expert and thoughtful discussion by the indomitable #JaniceLyons (not to mention fabulous colleague @RadOncUH ). Findings right in line with relevant elements of SKAGEN 1, HypoG-01, and Fast-Forward Nodal sub-study findings. But does one size fit all? Some words of caution for T4 disease, under represented here 🚩, and in those with residual modal disease after NAC. 🚩
Full house at our @RadOncUH#ASTRO2026 Meet & Greet! 🎯☢️
So much fun meeting the next generation of #RadOnc and introducing them to our residents and faculty. Thanks to everyone who came out—we may have taken over Flight Club just a little 💙
New #ASTRO2026 data from @NRGOnc /RTOG 0534 SPPORT 🔬🧬 presented by Shuang (George) Zhao @UTMDAnderson. PAM50 Luminal B = both prognostic & predictive of benefit from postop ADT.
📈 5-y FFP benefit: 31% vs 10% (p-int=.01)
🎯 10-y MFS: 20% vs -3% (p-int=.05)
#Pcsm@Astro_org
1/5 🧵 @NRGOnc GU003 5-y: HYPORT 62.5 Gy/25 fx increased G3 GU toxicity vs conventional RT (13% vs 3%) ⚠️, with no improvement in biochemical control.
BUT!!! Before we conclude hypofractionation is worse, take heed—this is a DOSE ESCALATION problem.